Inspire Medical Systems, Inc.
INSPHealthcareNASDAQMedical Devices · Last scanned Oct 26, 2026
Scan Results
Daily timeframeInspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the. The $2.06B market capitalization puts INSP squarely in mid-cap range for its industry. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for patients with moderate to severe OSA.
Market Cap
$2.06B
Beta
0.73
P/E (TTM)
15.66
P/E (Fwd)
46.28
EPS (TTM)
$4.54
EPS (Fwd)
$1.54
ROE
18.0%
ROA
3.9%
Cash
$320.7M
Total Debt
$29.1M
Free CF
$94.6M
52W Change
-9.1%
Annual Financials
Cash vs Debt
Where INSP stands vs its 150-day and 200-day moving averages
As of the October 9, 2026 close, INSP finished 22.34% above its 150-day moving average ($54.51) and 10.12% above its 200-day moving average ($60.56). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is INSP overbought or oversold?
At the October 9, 2026 close, INSP's RSI(14) was 29.2, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Inspire Medical Systems, Inc. holds $320.7M in cash against $29.1M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow comes in at $94.6M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 18.0% points to strong capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 3.9% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $407.9M (2022) to $912.0M (2025), reflecting a 124% increase over the period.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. No single metric tells the full story. Reviewing INSP's risk profile alongside its fundamentals and technical indicators provides a more complete picture.